Evidence map›Paper›PMID 38862238›Full record

ArticleBMJ open respiratory research2024

Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.

David Singer, Philippe Thompson-Leduc, Siyu Ma, Deepshekhar Gupta, Wendy Y Cheng, Aruna Muthukumar, Francesca Devine, Manasvi Sundar, Michael Bogart, Ella Hagopian and 3 more

Abstract read
In one paragraph

Article in BMJ open respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Herpes Zoster in Aging Patients: Risk Factors and Prevention Strategies.International journal of general medicine · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

David SingerGSK, Philadelphia, Pennsylvania, USA david.a.singer@gsk.com.ORCID http://orcid.org/0000-0001-8008-8003
Philippe Thompson-LeducAnalysis Group Inc, Montreal, Quebec, Canada.
Siyu MaGSK/Tufts Medical Center, Boston, Massachusetts, USA.
Deepshekhar GuptaAnalysis Group Inc, Menlo Park, California, USA.
Wendy Y ChengAnalysis Group Inc, Boston, Massachusetts, USA.
Aruna MuthukumarAnalysis Group Inc, Menlo Park, California, USA.
Francesca DevineAnalysis Group Inc, New York, New York, USA.
Manasvi SundarAnalysis Group Inc, Los Angeles, California, USA.
Michael BogartGSK, Research Triangle Park, North Carolina, USA.
Ella HagopianAnalysis Group Inc, Boston, Massachusetts, USA.
Sara PostonGSK, Philadelphia, Pennsylvania, USA.
Mei Sheng DuhAnalysis Group Inc, Boston, Massachusetts, USA.
John J OppenheimerRutgers New Jersey Medical School, Newark, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHerpes zoster (HZ) is a painful condition caused by reactivation of the varicella-zoster virus. The objectives of this study were to compare HZ incidence in adults with asthma versus adults without asthma and to compare healthcare resource use as well as direct costs in adults with HZ and asthma versus adults with asthma alone in the USA.

methodsThis retrospective longitudinal cohort study included adults aged ≥18 years across the USA. Patients were identified from Optum's deidentified Clinformatics Data Mart Database, an administrative claims database, between 1 October 2015 and 28 February 2020, including commercially insured and Medicare Advantage with part D beneficiaries. Cohorts of patients with and without asthma, and separate cohorts of patients with asthma and HZ and with asthma but not HZ, were identified using International Classification of Diseases 10th Revision, Clinical Modification codes. HZ incidence, healthcare resource use and costs were compared, adjusting for baseline characteristics, between the relevant cohorts using generalised linear models.

resultsHZ incidence was higher in patients with asthma (11.59 per 1000 person-years) than patients without asthma (7.16 per 1000 person-years). The adjusted incidence rate ratio (aIRR) for HZ in patients with asthma, compared with patients without asthma, was 1.34 (95% CI 1.32 to 1.37). Over 12 months of follow-up, patients with asthma and HZ had more inpatient stays (aIRR 1.11; 95% CI 1.02 to 1.21), emergency department visits (aIRR 1.26; 95% CI 1.18 to 1.34) and outpatient visits (aIRR 1.19; 95% CI 1.16 to 1.22), and direct healthcare costs that were US dollars ($) 3058 (95% CI $1671 to $4492) higher than patients with asthma without HZ.

conclusionPatients with asthma had a higher incidence of HZ than those without asthma, and among patients with asthma HZ added to their healthcare resource use and costs.

Indexed as

AsthmaHealth Care CostsHerpes ZosterAdolescentAdultAgedCost of IllnessFemaleHealth ResourcesHospitalizationHumansIncidenceLongitudinal StudiesMaleMiddle AgedPatient Acceptance of Health CareAsthmaAsthma EpidemiologyHealth EconomistViral infection

Identifiers

PMID38862238
PMCPMC11168123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.